Literature DB >> 11319610

CD95 ligand (CD95L) immunohistochemistry: a critical study on 12 antibodies.

J Sträter1, H Walczak, C Hasel, I Melzner, F Leithäuser, P Möller.   

Abstract

In recent years, some studies on the expression of CD95(Fas/APO-1) ligand (CD95L) in tissues or cells raised concerns about the specificity of the antibodies used. We therefore tested 12 CD95L antibodies for their reliability in immunocyto/histochemistry by (i) staining CD95L-transfected and control CV-1/EBNA cells and (ii) comparing staining patterns in immunohistochemically labeled tissue sections with the localization of CD95L+ cells in in situ hybridization. While G247-4, NOK-1, NOK-2, 4H9, and MIKE-1 stained CD95L-transfected cells and did not significantly bind to controls, G247-4 was the only antibody giving satisfying signals in tissue sections perfectly matching the distribution of CD95L+ cells by in situ hybridization. MAb 33, C-20, and N-20 comparably stained both transfected and control cells and showed considerable background or falsely positive staining in sections. MIKE-2, 8B8, A11, and 4A5 did not or only very faintly bind to either cells and, thus, were not tested on sections. We conclude that G247-4 is the only tested antibody that is recommendable for immunohistochemistry.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11319610     DOI: 10.1038/sj.cdd.4400813

Source DB:  PubMed          Journal:  Cell Death Differ        ISSN: 1350-9047            Impact factor:   15.828


  11 in total

1.  Endothelial Fas-Ligand in Inflammatory Bowel Diseases and in Acute Appendicitis.

Authors:  Tuomo S Kokkonen; Tuomo J Karttunen
Journal:  J Histochem Cytochem       Date:  2015-09-15       Impact factor: 2.479

2.  FasL and TRAIL induce epidermal apoptosis and skin ulceration upon exposure to Leishmania major.

Authors:  Liv Eidsmo; Caroline Fluur; Bence Rethi; Sofia Eriksson Ygberg; Nicolas Ruffin; Angelo De Milito; Hannah Akuffo; Francesca Chiodi
Journal:  Am J Pathol       Date:  2007-01       Impact factor: 4.307

3.  Lack of specificity of commercially available antisera: better specifications needed.

Authors:  Wisuit Pradidarcheep; Wil T Labruyère; Noshir F Dabhoiwala; Wouter H Lamers
Journal:  J Histochem Cytochem       Date:  2008-09-15       Impact factor: 2.479

4.  The contribution of the Fas/FasL apoptotic pathway in ulcer formation during Leishmania major-induced cutaneous Leishmaniasis.

Authors:  Liv Eidsmo; Susanne Nylen; Ali Khamesipour; Mari-Anne Hedblad; Francesca Chiodi; Hannah Akuffo
Journal:  Am J Pathol       Date:  2005-04       Impact factor: 4.307

5.  Impaired CD95 expression predisposes for recurrence in curatively resected colon carcinoma: clinical evidence for immunoselection and CD95L mediated control of minimal residual disease.

Authors:  J Sträter; U Hinz; C Hasel; U Bhanot; G Mechtersheimer; T Lehnert; P Möller
Journal:  Gut       Date:  2005-05       Impact factor: 23.059

6.  Up-regulation of Fas ligand (FasL) in the central nervous system: a mechanism of immune evasion by rabies virus.

Authors:  Leïla Baloul; Serge Camelo; Monique Lafon
Journal:  J Neurovirol       Date:  2004-12       Impact factor: 2.643

Review 7.  CD95 (Fas/APO-1)/CD95L in the gastrointestinal tract: fictions and facts.

Authors:  J Sträter; P Möller
Journal:  Virchows Arch       Date:  2003-02-11       Impact factor: 4.064

8.  Immunohistochemical study of the apoptotic mechanisms in the intestinal mucosa during children's coeliac disease.

Authors:  Jirí Ehrmann; Antonín Kolek; Rostislav Kod'ousek; Jana Zapletalová; Sona Lísová; Paul Gerard Murray; Jirí Drábek; Zdenek Kolár
Journal:  Virchows Arch       Date:  2003-04-16       Impact factor: 4.064

9.  Fas ligand expression in human and mouse cancer cell lines; a caveat on over-reliance on mRNA data.

Authors:  Aideen E Ryan; Sinead Lane; Fergus Shanahan; Joe O'Connell; Aileen M Houston
Journal:  J Carcinog       Date:  2006-02-02

10.  Prognostic impact of FAS/CD95/APO-1 in urothelial cancers: decreased expression of Fas is associated with disease progression.

Authors:  K Yamana; V Bilim; N Hara; T Kasahara; T Itoi; R Maruyama; T Nishiyama; K Takahashi; Y Tomita
Journal:  Br J Cancer       Date:  2005-09-05       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.